CClinicalTrials.gg
CompletedNCT05018377Updated Feb 5, 2025

Effectiveness and Safety of Percutaneous Adhesiolysis Using Rac'z Catheter Versus Navi Catheter in Management of Failed Back Surgery Syndrome

An interventional study of Racz adhesolysis and NAVI adhesolysis in Failed Back Surgery Syndrome, sponsored by Assiut University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-05.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2022, 4 years 1 month ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In the past decade, spine surgery rates have dramatically increased in parallel to those of other procedural interventions. Persistent pain is a common occurrence after spine surgery, with the most commonly quoted prevalence rates ranging from 10% to 40%. This pain can be classified into failure to alleviate baseline pain, pain resulting from complications (e.g., arachnoiditis and epidural adhesions), and pain that ensues several years later as a sequele to alterations in spinal architecture and biomechanics (e.g., adjacent segment discogenic or facetogenic pain) which is called failed back surgery syndrome ( FBSS )

Read the detailed description

By observing adhesions directly, the lysis of scar tissue can be carried out mechanically using some percutaneous techniques as insertion of catheters as Rac'z catheter (thin in calibre) which will be inserted through the skin under fluoroscopy guidance or using NAVI catheter (large in calibre) either fluoroscopy guided or using thin epiduroscopy. Adhesions can be disintegrated and their evaluation scores may improve.

02

Conditions studied

  • Failed Back Surgery Syndrome
03

In context

Syndrome

9,217 studies on the registry are indexed under Syndrome; 1,031 are open to participants now.

This study's enrollment of 60 is above the median of 50 across 6,515 interventional studies indexed under Syndrome.

Browse Syndrome studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with history of lumbar surgery of at least 6 months duration in the past.
  • Patients over the 18 years of age.
  • History of persistent function-limiting lower extremity pain aggravated by "dural tug" (observed when the patient, sitting on the exam table with legs stretched out, bends forward, bringing on the back pain) with or without low back pain of at least 6 months duration after failure of conventional conservative management in most patients including NSAIDS, muscle relaxants (tizanidine, magnesium sulphate) and pregabalin.
  • Patients who are competent to understand the study protocol and provide voluntary, written informed consent and participate in outcome measurements.

Exclusion criteria

Exclusion Criteria:

  • Unstable or heavy opioid use.
  • Uncontrolled psychiatric disorders.
  • Uncontrolled medical illness.
  • Any conditions that could interfere with the interpretation of the outcome assessments.
  • Pregnant or lactating women.
  • Patients with a history or potential for adverse reaction(s) to local anaesthetics or steroid.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Raj'z catheter

    Procedure: Racz adhesolysis

  • Active comparator
    NAVI catheter

    Device: NAVI adhesolysis

Interventions

  • ProcedureRacz adhesolysis

    adhesiolysis in failed back surgery

  • DeviceNAVI adhesolysis

    adhesiolysis in failed back surgery

06

What researchers measure

Primary outcomes

  1. numerical rating scale

    The VAS score was used that has 0-10 points. The 0 point represents the painless state and a score from 1 to 3 points represents mild pain, from 4 to 6 points represents moderate pain and from 7 to 10 points represents severe pain.

    Time frame: 12 months

Secondary outcomes

  1. Oswestry Disability Index (ODI)

    0 - 100% disability; minimal disability = 0% to either bed-bound or exaggerating symptoms = 100%)

    Time frame: 12 month

  2. pregabalin consumption

    amount of pregabalin consumed by the patient per day

    Time frame: 12 month

07

Study locations

1 site
  • Saeid Metwaly Elsawy
    Assiut, 71111, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided — may i share it

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05018377
Lead sponsor
Assiut University
Responsible party
Saeid Metwaly Abouelyazid Elsawy (lecturer of anesthesia, Assiut University) — Principal investigator
First posted
Aug 24, 2021
Start date
Sep 1, 2021
Primary completion
Sep 1, 2022
Completion
Aug 13, 2023
Last update
Feb 5, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion